|
@@ -5,18 +5,18 @@
|
|
|
<p class="antibodyDetail_title">Adalimumab</p>
|
|
|
<div class="antibodyDetail_box">
|
|
|
<p class="Detail_boxTitle">Summary</p>
|
|
|
- <div class="Detail_boxContent">Adalimumab is a monoclonal anti-tumor necrosis factor alpha antibody used inthe treatment of a wide variety of inflammatory conditions such as rheumatoidarthritis, Crohn's disease, and ankylosing spondylitis.</div>
|
|
|
+ <div class="Detail_boxContent">{{ overView.summary }}</div>
|
|
|
</div>
|
|
|
<div class="antibodyDetail_box">
|
|
|
<p class="Detail_boxTitle">Background</p>
|
|
|
<div class="Background_box">
|
|
|
<div class="Background_content Detail_line">
|
|
|
<p class="Background_title">Relationship to Disease</p>
|
|
|
- <p class="Background_text">Adalimumab is a subcutaneously administered biological diseasemodifier for the treatment of rheumatoid arthritis and other chronicdebilitating diseases mediated by tumor necrosis factor</p>
|
|
|
+ <p class="Background_text">{{ overView.relationshipToDisease }}</p>
|
|
|
</div>
|
|
|
<div class="Background_content">
|
|
|
<p class="Background_title">Mechanism of action</p>
|
|
|
- <p class="Background_text">Adalimumab binds with specificity to tumor necrosis factor-alpha(TNF-alpha) and inhibits its interaction with the p55 and p75 cellsurface TNF receptors.Increased levels of TNF are also measured inpsoriasis plaques. In plaque psoriasis, treatment with adalimumabmay decrease the epidermal thickness and inflammatory cellinfiltration.</p>
|
|
|
+ <p class="Background_text">{{ overView.mechanismOfActionOne }}</p>
|
|
|
</div>
|
|
|
</div>
|
|
|
</div>
|
|
@@ -27,27 +27,27 @@
|
|
|
<div class="Properties_content">
|
|
|
<div class="Background_content Detail_line">
|
|
|
<p class="Background_title">Company</p>
|
|
|
- <p class="Background_text">Abbvie</p>
|
|
|
+ <p class="Background_text">{{ overView.company }}</p>
|
|
|
</div>
|
|
|
<div class="Background_content Detail_line">
|
|
|
<p class="Background_title">Actions</p>
|
|
|
- <p class="Background_text">Inhibitor antibody</p>
|
|
|
+ <p class="Background_text">{{ overView.actions }}</p>
|
|
|
</div>
|
|
|
<div class="Background_content Detail_line">
|
|
|
<p class="Background_title">Heavy chain type</p>
|
|
|
- <p class="Background_text">IgG1</p>
|
|
|
+ <p class="Background_text">{{ overView.heavyChainType }}</p>
|
|
|
</div>
|
|
|
<div class="Background_content Detail_line">
|
|
|
<p class="Background_title">Bioavailability</p>
|
|
|
- <p class="Background_text">64% (subcutaneous), 0% (By mouth)</p>
|
|
|
+ <p class="Background_text">{{ overView.bioavailability }}</p>
|
|
|
</div>
|
|
|
<div class="Background_content Detail_line">
|
|
|
<p class="Background_title">Generic Name</p>
|
|
|
- <p class="Background_text">Adalimumab</p>
|
|
|
+ <p class="Background_text">{{ overView.genericName }}</p>
|
|
|
</div>
|
|
|
<div class="Background_content Detail_line">
|
|
|
<p class="Background_title">Source</p>
|
|
|
- <p class="Background_text">Phage display</p>
|
|
|
+ <p class="Background_text">{{ overView.source }}</p>
|
|
|
</div>
|
|
|
<div class="Background_content">
|
|
|
<p class="Background_title">Conditions</p>
|
|
@@ -65,35 +65,35 @@
|
|
|
</div>
|
|
|
<div class="Properties_content Properties_Right">
|
|
|
<div class="Background_content Detail_line">
|
|
|
- <p class="Background_title">Company</p>
|
|
|
- <p class="Background_text">Abbvie</p>
|
|
|
+ <p class="Background_title">Brand names</p>
|
|
|
+ <p class="Background_text">{{ overView.source }}</p>
|
|
|
</div>
|
|
|
<div class="Background_content Detail_line">
|
|
|
- <p class="Background_title">Actions</p>
|
|
|
- <p class="Background_text">Inhibitor antibody</p>
|
|
|
+ <p class="Background_title">Biologic Classification</p>
|
|
|
+ <p class="Background_text">{{ overView.source }}</p>
|
|
|
</div>
|
|
|
<div class="Background_content Detail_line">
|
|
|
- <p class="Background_title">Heavy chain type</p>
|
|
|
+ <p class="Background_title">Target</p>
|
|
|
<p class="Background_text">IgG1</p>
|
|
|
</div>
|
|
|
<div class="Background_content Detail_line">
|
|
|
- <p class="Background_title">Bioavailability</p>
|
|
|
+ <p class="Background_title">Other Name</p>
|
|
|
<p class="Background_text">64% (subcutaneous), 0% (By mouth)</p>
|
|
|
</div>
|
|
|
<div class="Background_content Detail_line">
|
|
|
- <p class="Background_title">Generic Name</p>
|
|
|
+ <p class="Background_title">Light chain type</p>
|
|
|
<p class="Background_text">Adalimumab</p>
|
|
|
</div>
|
|
|
<div class="Background_content Detail_line">
|
|
|
- <p class="Background_title">Source</p>
|
|
|
+ <p class="Background_title">Half-life</p>
|
|
|
<p class="Background_text">Phage display</p>
|
|
|
</div>
|
|
|
<div class="Background_content Detail_line">
|
|
|
- <p class="Background_title">Source</p>
|
|
|
+ <p class="Background_title">Protein Weight (KDa)</p>
|
|
|
<p class="Background_text">Phage display</p>
|
|
|
</div>
|
|
|
<div class="Background_content" style="min-height: 130px;">
|
|
|
- <p class="Background_title">Conditions</p>
|
|
|
+ <p class="Background_title">Structure</p>
|
|
|
<p class="Background_text" style="min-height: 130px;">
|
|
|
</p>
|
|
|
</div>
|
|
@@ -105,11 +105,11 @@
|
|
|
<p class="Detail_boxTitle">Clinical Trials</p>
|
|
|
<div class="Clinical_box">
|
|
|
<div class="Clinical_top Detail_line">
|
|
|
+ <p class="Background_title line_right">NCT Number</p>
|
|
|
+ <p class="Background_title line_right">Stage</p>
|
|
|
+ <p class="Background_title line_right">Status</p>
|
|
|
<p class="Background_title line_right">Company</p>
|
|
|
- <p class="Background_title line_right">Company</p>
|
|
|
- <p class="Background_title line_right">Company</p>
|
|
|
- <p class="Background_title line_right">Company</p>
|
|
|
- <p class="Background_text">Company</p>
|
|
|
+ <p class="Background_text">Condition</p>
|
|
|
</div>
|
|
|
<div class="Clinical_scoll">
|
|
|
<div class="Background_content Detail_line">
|
|
@@ -162,11 +162,11 @@
|
|
|
<p class="Detail_boxTitle">Toxicity and side effects</p>
|
|
|
<div class="Background_box">
|
|
|
<div class="Background_content Detail_line">
|
|
|
- <p class="Background_title">Relationship to Disease</p>
|
|
|
+ <p class="Background_title">Toxicity</p>
|
|
|
<p class="Background_text">Adalimumab is a subcutaneously administered biological diseasemodifier for the treatment of rheumatoid arthritis and other chronicdebilitating diseases mediated by tumor necrosis factor</p>
|
|
|
</div>
|
|
|
<div class="Background_content">
|
|
|
- <p class="Background_title">Mechanism of action</p>
|
|
|
+ <p class="Background_title">Mechanism ofaction</p>
|
|
|
<p class="Background_text">Adalimumab binds with specificity to tumor necrosis factor-alpha(TNF-alpha) and inhibits its interaction with the p55 and p75 cellsurface TNF receptors.Increased levels of TNF are also measured inpsoriasis plaques. In plaque psoriasis, treatment with adalimumabmay decrease the epidermal thickness and inflammatory cellinfiltration.</p>
|
|
|
</div>
|
|
|
</div>
|